12 November 2025 Sydney, Australia

Nyrada AGM 2025 Chair's Address

Good morning, ladies and gentlemen.

My name is John Moore, and I have the privilege of serving as the Non-Executive Chair of Nyrada Inc. On behalf of the Board of Directors, I am delighted to welcome you to our 2025 Annual General Meeting. Thank you for joining us today, whether in person or online.

It is wonderful to see so many of you here as we reflect on a year of remarkable progress and transformation for our company.

Before we move to the formal proceedings, I would like to take a few moments to share some reflections on Nyrada's mission, our progress, and the journey that lies ahead.

Nyrada exists at the intersection of discovery and purpose. Our focus is drug discovery and early-stage development: two of the most crucial, challenging, and rewarding phases in modern medicine. These are the stages where ideas become possibilities and where science first begins to shape the future of human health.

Over the past few decades, as humanity's understanding of disease biology has deepened, new molecular pathways have emerged enabling us to target the underlying causes of conditions once thought untreatable. At Nyrada, we are proud to contribute to that progress, pursuing treatments that can improve lives while creating meaningful value for our shareholders.

Drug development is often described as navigating uncharted waters. It requires courage, clarity, and persistence in the face of uncertainty. Our lead drug candidate, Xolatryp™, formerly NYR-BI03, is a first-in-class small molecule therapy that targets Transient Receptor Potential Canonical channels or as we call them TRPC (trip-see) 3, 6, and 7 channels. TRPC channels are a family of calcium-permeable ion channels are key mediators of calcium dysregulation that follows trauma.

Our focus on TRPC channel inhibition positions us at the forefront of a new generation of therapies aimed at addressing some of the most pressing unmet needs in medicine.

Having successfully completed our Phase I clinical trial, we now sit at the cusp of commencing our Phase IIa trial to evaluate Xolatryp as a first-in-class intravenous treatment to reduce myocardial injury following ischemia in patients who undergo primary PCI.

This is the final frontier in the treatment of acute coronary disease. The trial will assess safety, and preliminary efficacy of Xolatryp.

We expect to submit our regulatory package very soon and, subject to approval, expect to commence patient dosing in March next year.

Beyond our focus on cardioprotection, we additionally continue to explore the broader therapeutic potential of TRPC inhibition. Emerging research suggests opportunities in autoimmune, pulmonary, and oncological diseases. While our current focus remains on successfully completing our Phase IIa trial, the science opens doors to a wide array of future applications, and we are well-positioned to pursue them.

I am not one to generally quote Vladimir Lenin but allow me to paraphrase him for this occasion: “There are years where nothing happens, and there are months where decades happen.” For Nyrada, the past 18 months have felt like many decades have happened.

Since announcing the results of our stroke study in February 2024, we have achieved an extraordinary series of milestones:

We demonstrated preclinical efficacy in two additional major and underserved indications in traumatic brain injury and myocardial ischemia reperfusion injury.

To enable us to undertake our Phase I clinical trial, we successfully initiated and completed GLP testing.

To undertake our coming Phase IIa clinical trial, we similarly and successfully initiated and completed a Phase I clinical trial.

To undertake these developments, we also successfully completed three successful capital raises, each an up round, raising $13.7 million.

And over this period, the price of our securities has increased, remarkably, from below 2 cents to an all-time high of $1.05 cents last week on 5 November.

This has been an extraordinary and impactful period for the Company.

Throughout, it has been a period defined by scientific breakthroughs, clinical progress, and a strengthening of our commitment to turning world-class biomedical research into life-changing therapies. As our corporate tagline says: “Improving Lives, Offering Hope.”

Our progress also places the company at an important value inflection point.

In Australia, early-stage biotech funding tends to concentrate before human trials begin, leaving a gap as companies advance into the clinical stage. With Xolatryp already demonstrating both preclinical efficacy and early human safety, Nyrada is now exceptionally well-positioned to capture substantial value as we move into efficacy studies.

Our Managing Director and CEO, James Bonnar, has built a talented and dedicated team, uniting deep expertise in chemistry, biology, pharmacology, and clinical development. Under his leadership, and with the support of our distinguished Scientific Advisory Board chaired by Professor Gary Housley, we continue to drive innovation with discipline, focus, and ambition.

Our Board also brings extensive experience and strategic networks that will be invaluable as we seek to commercialise Xolatryp across multiple high-impact therapeutic areas.

Australia continues to be an outstanding environment for drug development, offering a strong R&D rebate framework, world-class research infrastructure, and a rich pool of scientific talent.

As we look forward, our priorities are clear: to commence our Phase IIa safety and efficacy study, continue expanding our TRPC-target pipeline, and to translate our discoveries into therapies that make a real difference. We are not just developing a drug; we are building a platform, a team, and a vision for a healthier tomorrow.

Before I conclude, I would like to extend my sincere thanks to my fellow Non-Executive Directors for their diligence and guidance, to James Bonnar for his leadership, and to the entire Nyrada team for their dedication, ingenuity, and perseverance throughout the 2025 financial year. I would additionally like to recognise and thank Dr Gisela Mautner who retires from the board at the conclusion of this meeting.

Finally, to our CDI holders, thank you for your ongoing trust, support, and belief in what we are building. Together, we are not just progressing a therapy: we are shaping the future.

As I often like to say to my friends and colleagues: adventure awaits.

Thank you for your attention and for joining us today as we continue our adventure.

John Moore

Non-Executive Chair

– ENDs –

About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp™, has shown efficacy in both cardioprotection and neuroprotection, and has just completed a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by John Moore, Non-Executive Chair, on behalf of the Board.

Investor & Media Enquiries:
Dimitri Burshtein
T: 0491 789 391
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.